Limiting the development of anti-cancer drug resistance in a spatial model of micrometastases

Ami B. Shah, Katarzyna A. Rejniak, Jana L. Gevertz

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


While chemoresistance in primary tumors is well-studied, much less is known about the influence of systemic chemotherapy on the development of drug resistance at metastatic sites. In this work, we use a hybrid spatial model of tumor response to a DNA damaging drug to study how the development of chemoresistance in micrometastases depends on the drug dosing schedule. We separately consider cell populations that harbor pre-existing resistance to the drug, and those that acquire resistance during the course of treatment. For each of these independent scenarios, we consider one hypothetical cell line that is responsive to metronomic chemotherapy, and another that with high probability cannot be eradicated by a metronomic protocol. Motivated by experimental work on ovarian cancer xenografts, we consider all possible combinations of a one week treatment protocol, repeated for three weeks, and constrained by the total weekly drug dose. Simulations reveal a small number of fractionated-dose protocols that are at least as effective as metronomic therapy in eradicating micrometastases with acquired resistance (weak or strong), while also being at least as effective on those that harbor weakly pre-existing resistant cells. Given the responsiveness of very different theoretical cell lines to these few fractionated-dose protocols, these may represent more effective ways to schedule chemotherapy with the goal of limiting metastatic tumor progression.

Original languageEnglish
Pages (from-to)1185-1206
Number of pages22
JournalMathematical Biosciences and Engineering
Issue number6
StatePublished - Dec 2016
Externally publishedYes


  • Chemoresistance
  • Fractionated therapy
  • Hybrid model
  • Maximum tolerated dose
  • Metronomic chemotherapy
  • Micrometastases


Dive into the research topics of 'Limiting the development of anti-cancer drug resistance in a spatial model of micrometastases'. Together they form a unique fingerprint.

Cite this